Concepedia

Publication | Closed Access

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

DOI

60

Citations

26

References

2018

Year

Richard B. Lipton, Alan Brennan, Stephen Palmer, Anthony J. Hatswell, J. Porter, Sandhya Sapra, Guillermo Villa, Neel Shah, Stewart J. Tepper, David W. Dodick
Journal of Medical Economics

Abstract

Erenumab is predicted to reduce migraine-related direct and indirect costs, and increase QALYs compared to SC.

References

YearCitations

Page 1